These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Estradiol receptor levels in human breast carcinomas.
    Author: Bird CE, Houghton B, Westenbrink W, Tenniswood M, Sterns EE, Clark AF.
    Journal: Can Med Assoc J; 1981 Apr 15; 124(8):1010-2. PubMed ID: 7260784.
    Abstract:
    The presence or absence of a specific estradiol-binding protein receptor in the cytoplasm of primary and secondary tumour cells has been used by physicians as an important guide in deciding whether to use hormonal therapy for patients with metastatic breast cancer. This report gives the levels of estradiol receptors in the cytosol of 228 primary and secondary breast tumours, measured by a sensitive multiple-point assay in which dextran-coated charcoal separated bound form unbound estrogen. The data were analysed with a Scatchard plot. Of the 175 primary and 53 secondary tumours 53% and 32% respectively gave positive results. The mean receptor level in the primary tumours was significantly higher among older patients and increased with age. With metastatic lesions positive results were more common in lymph node samples tha in skin nodule samples. The presence or absence of a specific estradiol-binding protein receptor in tumor cells is believed to be a significant guide as to whether the tumor will respond to ablative or additive hormone therapy. Clinical research directed at identifying the presence of estrogen receptors in breast tumors is described. Cytosol receptor analysis was conducted on 228 tumors, 175 primary and 53 secondary. 53% of the primary and 32% of the secondary tumors gave positive results when tested for the presence of estrogen receptors. The proportion of positive samples did not increase with age, but the mean amount of estradiol bound to the receptors of both the primary and the secondary tumors did. Mean amounts were higher for primary than for secondary tumors at every age group in which the quantities were great enough for comparisons. The finding of a higher mean receptor level in older patients confirms findings of previous studies; this finding is explained partially by decreased serum estradiol levels in postmenopausal women. The study has not been conducted long enough to correlate levels of estradiol receptor in breast cancers with effectiveness of hormone therapy for metastatic disease; analysis of this treatment will continue.
    [Abstract] [Full Text] [Related] [New Search]